Carlos Arthur Fernandes Sobreira
Research Subjects
Carlos Arthur Fernandes Sobreira has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Anna Sara Levin
Universidade de São Paulo, Brasil
1 shared publication Bárbara Silva Gomes
1 shared publication- Caio César Furtado Freire
Hospital Geral Dr. César Cals, Brasil
1 shared publication - Camila Ribeiro Rôla
Centro Universitário Christus (UniChristus), Brasil
1 shared publication - Carola Braz de Lavor
Centro Universitário Christus (UniChristus), Brasil
1 shared publication - Clara Farias Otoni
Centro Universitário Unichristus
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 61, e23195
COVID-19 IN INFLAMMATORY BOWEL DISEASE: SHOULD WE BE MORE CAREFUL WITH THE USE OF SALICYLATES?
Backgrounds: Fortunately, much has been studied about COVID-19 in patients with inflammatory bowel diseases (IBD). Evidence suggests that these patients do not appear to be at increased risk of severe COVID-19. However, there are still some uncertainties regarding the clinical manifestations of COVID-19 in patients with immune-mediated diseases. Objective: This study aimed to describe the main symptoms of COVID-19 and their frequency in IBD patients and evaluate the impact of the IBD therapeutic drugs on clinical presentation of COVID-19 and to determine factors associated with COVID-19 in this population. Methods: Adult patients with IBD from three tertiary-care public, teaching hospitals in Ceará, Northeastern Brazil, were evaluated during one scheduled appointment from March to December 2020. Patients with possible or confirmed COVID-19 were compared with patients without COVID-19. Furthermore, incidences of each symptom were evaluated based on the use of IBD therapeutic drugs. Results: A total of 515 patients with IBD were included in the study: 234 with CD, and 281 with UC. Of these, 174 patients (34%) had possible/confirmed COVID-19 of whom 156 (90%) were symptomatic. Main symptoms were fever (65%) and headache (65%); gastrointestinal symptoms occurred in one third of patients and were higher than COVID-19 in general population. The factors associated with having COVID-19 were female gender (OR 1.71, 95%CI: 1.17-2.50); contact at home (OR 5.07, 95%CI: 3.31-7.78) and outside the home (OR 3.14, 95%CI: 2.10-4.71) with a case of COVID-19; work outside of the home (OR 1.87, 95%CI: 1.26-2.78); family history of COVID-19 (OR 2.29, 95%CI 1.58-3.33) use of salicylate (OR 1.71, 95%CI: 1.17-4.28); and asthma (OR 7.10, 95%CI: 1.46-34.57). Conclusion: IBD patients at high risk of COVID-19 infection may need to avoid salicylate therapy but further studies are necessary to confirm this association.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Arquivos de Gastroenterologia
- Vol. 61, e23195
Open AccessCOVID-19 IN INFLAMMATORY BOWEL DISEASE: SHOULD WE BE MORE CAREFUL WITH THE USE OF SALICYLATES?
Backgrounds: Fortunately, much has been studied about COVID-19 in patients with inflammatory bowel diseases (IBD). Evidence suggests that these patients do not appear to be at increased risk of severe COVID-19. However, there are still some uncertainties regarding the clinical manifestations of COVID-19 in patients with immune-mediated diseases. Objective: This study aimed to describe the main symptoms of COVID-19 and their frequency in IBD patients and evaluate the impact of the IBD therapeutic drugs on clinical presentation of COVID-19 and to determine factors associated with COVID-19 in this population. Methods: Adult patients with IBD from three tertiary-care public, teaching hospitals in Ceará, Northeastern Brazil, were evaluated during one scheduled appointment from March to December 2020. Patients with possible or confirmed COVID-19 were compared with patients without COVID-19. Furthermore, incidences of each symptom were evaluated based on the use of IBD therapeutic drugs. Results: A total of 515 patients with IBD were included in the study: 234 with CD, and 281 with UC. Of these, 174 patients (34%) had possible/confirmed COVID-19 of whom 156 (90%) were symptomatic. Main symptoms were fever (65%) and headache (65%); gastrointestinal symptoms occurred in one third of patients and were higher than COVID-19 in general population. The factors associated with having COVID-19 were female gender (OR 1.71, 95%CI: 1.17-2.50); contact at home (OR 5.07, 95%CI: 3.31-7.78) and outside the home (OR 3.14, 95%CI: 2.10-4.71) with a case of COVID-19; work outside of the home (OR 1.87, 95%CI: 1.26-2.78); family history of COVID-19 (OR 2.29, 95%CI 1.58-3.33) use of salicylate (OR 1.71, 95%CI: 1.17-4.28); and asthma (OR 7.10, 95%CI: 1.46-34.57). Conclusion: IBD patients at high risk of COVID-19 infection may need to avoid salicylate therapy but further studies are necessary to confirm this association.
- Open Access
- 14 February 2023
- Published by Research, Society and Development in Research, Society and Development
- Vol. 12 (3)
Avaliação da disfunção do sistema renal relacionado ao HIV
Patients with HIV infection may have different causes and manifestations for kidney disease, from subclinical proteinuria to acute renal failure. It can be caused both by the direct effect of HIV on the kidneys and by the nephrotoxic effect of antiretroviral medications. The objective of this study is to evaluate renal dysfunction and relate it to the glomerular filtration rate (GFR) of patients followed up in a reference outpatient clinic for patients living with HIV/AIDS (PLWHA). This is a cross-sectional, retrospective, non-interventionist study, carried out by reviewing the medical records of patients treated from 2017 to 2020, at the HIV outpatient clinic of a reference quaternary hospital in Fortaleza, Ceará, Brazil. The results evaluated 77 patients, aged between 32 and 77 years, 63.6% male and 35.1% female, in addition to 1.3% transsexual (N=1). 113 measurements of renal function markers were analyzed and correlated with the calculation of glomerular filtration rate (GFR) through age and the creatinine value by the MDRD GFR equation, with 32.7% (N=37) with normal GFR. The mean MDRD was 81.7 mL/min/1.73m2, mean protein/creatinuria ratio 0.16 (N=69) and mean beta2microglobulin of 2.4 ng/ml, with 60.5% of altered dosages (> two). Most frequent comorbidities: Diabetes mellitus (27.3%), SAH (22%), Dyslipidemia (28.6%) and kidney disease 14.3%). The preferred regimen, tenofovir, lamivudine and dolutegravir, was used by 33% of patients; 5.4% followed a simplified scheme with lamivudine and dolutegravir. Detectable viral load found in 9.8% of records. We conclude that patients have a high prevalence of kidney disease in PLWHA that correlate with the presence of comorbidities and tubular changes.
- 14 February 2023
- Published by Research, Society and Development in Research, Society and Development
- Vol. 12 (3)
Open AccessAvaliação da disfunção do sistema renal relacionado ao HIV
Patients with HIV infection may have different causes and manifestations for kidney disease, from subclinical proteinuria to acute renal failure. It can be caused both by the direct effect of HIV on the kidneys and by the nephrotoxic effect of antiretroviral medications. The objective of this study is to evaluate renal dysfunction and relate it to the glomerular filtration rate (GFR) of patients followed up in a reference outpatient clinic for patients living with HIV/AIDS (PLWHA). This is a cross-sectional, retrospective, non-interventionist study, carried out by reviewing the medical records of patients treated from 2017 to 2020, at the HIV outpatient clinic of a reference quaternary hospital in Fortaleza, Ceará, Brazil. The results evaluated 77 patients, aged between 32 and 77 years, 63.6% male and 35.1% female, in addition to 1.3% transsexual (N=1). 113 measurements of renal function markers were analyzed and correlated with the calculation of glomerular filtration rate (GFR) through age and the creatinine value by the MDRD GFR equation, with 32.7% (N=37) with normal GFR. The mean MDRD was 81.7 mL/min/1.73m2, mean protein/creatinuria ratio 0.16 (N=69) and mean beta2microglobulin of 2.4 ng/ml, with 60.5% of altered dosages (> two). Most frequent comorbidities: Diabetes mellitus (27.3%), SAH (22%), Dyslipidemia (28.6%) and kidney disease 14.3%). The preferred regimen, tenofovir, lamivudine and dolutegravir, was used by 33% of patients; 5.4% followed a simplified scheme with lamivudine and dolutegravir. Detectable viral load found in 9.8% of records. We conclude that patients have a high prevalence of kidney disease in PLWHA that correlate with the presence of comorbidities and tubular changes.
- 1 January 2021
- Published by Even3
CAMPANHA DE PREVENÇÃO DO AVC PELA IFMSA BRAZIL UNICHRISTUS
Publicado em 19/05/2021 - ISBN 978-65-5941-206-8 - Unichristus
- 1 January 2021
- Published by Even3
CAMPANHA DE PREVENÇÃO DO AVC PELA IFMSA BRAZIL UNICHRISTUS
Publicado em 19/05/2021 - ISBN 978-65-5941-206-8 - Unichristus